Related Experiment Video
Updated: Jun 8, 2026
12:00
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
Published on: January 22, 2015
12.4K
Repaglinide-Solid Lipid Nanoparticles in Chitosan Patches for Transdermal Application: Box-Behnken Design,
Hany S M Ali1,2, Nader Namazi1, Hossein M Elbadawy3
1Department of Pharmaceutics and Pharmaceutical Industries, College of Pharmacy, Taibah University, Madinah, Al-Madinah Al-Munawwarah, Saudi Arabia.
International Journal of Nanomedicine
|January 15, 2024
Summary
This study developed a novel transdermal delivery system using repaglinide-solid lipid nanoparticles (REP-SLNs) in a chitosan base. The REP-SLN-TDDS enhanced drug bioavailability and effectively reduced blood glucose levels in rats.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Engineering
- Drug Delivery Systems
Background:
- Repaglinide (REP) exhibits poor oral bioavailability due to low solubility and extensive first-pass metabolism.
- Developing alternative delivery systems is crucial for improving REP's therapeutic efficacy.
Purpose of the Study:
- To engineer a biodegradable chitosan-based transdermal delivery system (REP-SLN-TDDS) loaded with repaglinide-solid lipid nanoparticles (REP-SLNs).
- To enhance REP's bioavailability and achieve controlled release via transdermal administration.
Main Methods:
- Fabrication of REP-SLNs using ultrasonic hot-melt emulsification.
- Optimization of processing variables (lipid content, surfactant concentration, sonication amplitude) using Box-Behnken design.
- Characterization of REP-SLN-TDDS for physicochemical properties, drug release kinetics, and ex vivo skin permeation.
- Assessment of pharmacokinetic and pharmacodynamic profiles in experimental rats.
Main Results:
- Optimized REP-SLNs achieved a particle size of 249±9.8 nm and entrapment efficiency of 78%±2.3%.
- The REP-SLN-TDDS showed sustained drug release (80% at 24 h) and significantly enhanced skin permeation (flux of 2.481±0.22 μg/cm²/h).
- The transdermal system maintained higher REP plasma levels and demonstrated superior blood glucose reduction compared to unprocessed REP and commercial tablets in rats.
Conclusions:
- The developed REP-SLN-TDDS offers an efficient strategy for repaglinide administration.
- This novel system holds promise for improving the therapeutic management of diabetes through enhanced bioavailability and sustained drug delivery.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...